Kronos Bio (KRON)
(Delayed Data from NSDQ)
$0.94 USD
-0.01 (-0.95%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $0.94 0.00 (-0.31%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Kronos Bio, Inc. (KRON) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.42 | $8.00 | $2.25 | 470.53% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Kronos Bio, Inc. comes to $5.42. The forecasts range from a low of $2.25 to a high of $8.00. The average price target represents an increase of 470.53% from the last closing price of $0.95.
Analyst Price Targets (3 )
Broker Rating
Kronos Bio, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/19/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
5/10/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $5.42 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.26 |
KRON FAQs
Kronos Bio, Inc. (KRON) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Kronos Bio, Inc. (KRON) is $5.42. The current on short-term price targets is based on 3 reports.
The forecasts for Kronos Bio, Inc. (KRON) range from a low of $2.25 to a high of $8. The average price target represents a increase of $476.60 from the last closing price of $.94.
The current UPSIDE for Kronos Bio, Inc. (KRON) is 476.60%
Based on short-term price targets offered by three analysts, the average price target for Kronos Bio, Inc. comes to $5.42. The forecasts range from a low of $2.25 to a high of $8.00. The average price target represents an increase of 470.53% from the last closing price of $0.95.